With over a decade of experience in life sciences and a background in commercial strategy and R&D, Matthew Birnbaum is set to drive the successful launch of TG-C, a groundbreaking cell and gene therapy for osteoarthritis.
Matthew Birnbaum has over a decade of experience in the life sciences industry. Before joining Kolon TissueGene this past September, Matthew was a commercial strategy consultant for Charles River Associates and bioStrategies Group. He specialized in brand planning, competitive intelligence, and commercial due diligence. He has also worked in research and development roles for Regeneron Pharmaceuticals, supporting BLA studies and discovery research.
“I am very excited to join the team at Kolon TissueGene as their Product Launch Specialist. There is a great unmet need to reduce pain and improve function for osteoarthritis patients. I look forward to being a part of KTG as we complete our phase 3 studies, move toward BLA filing, and build our commercial capabilities.”
About Kolon TissueGene, Inc.
Kolon TissueGene, Inc., is an advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting OA of the knee. The Company’s lead product, TG-C, is an allogeneic cell and gene therapy. The Company is conducting Phase 3 clinical trials in the US under a Special Protocol Assessment (SPA) agreement reached with the US FDA. Information about the trials can be found at the National Institutes of Health registry, www.clinicaltrials.gov. For additional information about Kolon TissueGene, Inc., please visit www.tissuegene.com.
Kolon TissueGene is developing TG-C, a first-in-class cell and gene therapy targeting OA of the knee through a single intra-articular injection. Clinical trials held in the US and abroad have demonstrated pain relief and increased mobility, as well as indicators towards decreased progression of OA and improvements in joint structure. The allogeneic (off-the-shelf) drug could provide an alternative to traditional treatment and surgery, or delay the progression of OA to minimize the need for multiple surgical interventions. In a concluded US Phase 2 clinical trial, Kolon TissueGene demonstrated a two-year improvement of pain and function. The Company seeks to continue to support these results through its Phase 3 clinical trials. In addition, the Company has designed the trials to seek a disease-modifying osteoarthritis drug (DMOAD) designation for TG-C from the US FDA—potentially making TG-C the first therapy to receive such a DMOAD label.
